Tracer library / [177Lu]Lu-BPAMD

Structure of BPAMD (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 66557879

[177Lu]Lu-BPAMD

Also written as [Lu-177]Lu-BPAMD

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 2

Bone metastases and bone lesions

What it is

Compound class: DOTA-conjugated bisphosphonate
Target / mechanism: Bone-seeking bisphosphonate with hydroxyapatite affinity for skeletal targeting PMID 41900797
Clinical application: Pain palliation and targeted endoradiotherapy of bone metastases and benign bone lesions PMID 25714451
Theranostic pair: [68Ga]Ga-BPAMD

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	>98%	>98%	BPAMD ABX	41900797 2026 Pharmaceutics Briefly, 74 MBq of [177Lu]LuCl3 was added in an aqueous solution containing 100 µg of BPAMD in 0.5 mL of sodium acetate buffer (0.4 M, pH 4.5). - Both complexes achieved a radiochemical yield of greater than 98%.
—	—	—	almost quantitative	—	BPAMD	25714451 2015 Cancer Biother Radiopharm An automated synthesis unit was designed for the production of therapeutic doses of [(177)Lu]BPAMD up to 5 GBq. - A Kit formulation combining BPAMD, acetate buffer, and ethanol resulted in almost quantitative labeling yields.

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: ABX
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-BPAMD, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 41900797: 'The ligand (4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (BPAMD) was purchased from ABX (Radeberg, Germany).'. Stage set/updated at stage 39 from PMID 25714451: 'The procedure was successfully applied for patient treatments.'.